Cargando…
On the Critical Issues in Temozolomide Research in Glioblastoma: Clinically Relevant Concentrations and MGMT-independent Resistance
The current standard first-line treatment for adult patients with newly diagnosed glioblastoma includes concurrent radiotherapy and daily oral temozolomide (TMZ), followed by adjuvant TMZ. As a prodrug, TMZ undergoes spontaneous hydrolysis generating a methylating agent. O(6)-methylguanine is consid...
Autores principales: | Stepanenko, Aleksei A., Chekhonin, Vladimir P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966644/ https://www.ncbi.nlm.nih.gov/pubmed/31783653 http://dx.doi.org/10.3390/biomedicines7040092 |
Ejemplares similares
-
Temozolomide promotes genomic and phenotypic changes in glioblastoma cells
por: Stepanenko, Aleksei A., et al.
Publicado: (2016) -
Advances in the management of glioblastoma: the role of temozolomide and MGMT testing
por: Thomas, Reena P, et al.
Publicado: (2012) -
Recent Advances in Oncolytic Virotherapy and Immunotherapy for Glioblastoma: A Glimmer of Hope in the Search for an Effective Therapy?
por: Stepanenko, Aleksei A., et al.
Publicado: (2018) -
A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma
por: Chen, Xiaoyue, et al.
Publicado: (2018) -
Epigenetic Activation of TUSC3 Sensitizes Glioblastoma to Temozolomide Independent of MGMT Promoter Methylation Status
por: Wu, Qiong, et al.
Publicado: (2023)